keyword
MENU ▼
Read by QxMD icon Read
search

Vlp

keyword
https://www.readbyqxmd.com/read/28103808/ventricular-late-potential-in-cardiac-syndrome-x-compared-to-coronary-artery-disease
#1
Mohamed Faisal Lutfi
BACKGROUND: Although ventricular late potential (VLP) was extensively studied in risk stratification of myocardial infarction (MI) patients, comparable researches evaluating presence of VLP in MI-free coronary artery disease (CAD) and cardiac syndrome X (CSX) subjects are scarce. This study aimed to compare presence of VLP between CSX and CAD patients. METHODS: Signal average ECG (SAECG) was performed to 49 patients with a history of typical cardiac pain before undergoing diagnostic coronary angiography (DCA) in Al-Shaab cardiac center, Khartoum, Sudan...
January 19, 2017: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/28093338/a-virus-like-particle-vaccination-strategy-expands-its-tolerance-to-h3n2-antigenic-drift-by-enhancing-neutralizing-antibodies-against-hemagglutinin-stalk
#2
Ji-Rong Yang, Chieh-Yu Cheng, Chih-Yuan Chen, Chao-Hua Lin, Chuan-Yi Kuo, Hsiang-Yi Huang, Fu-Ting Wu, Yu-Chih Yang, Chia-Ying Wu, Ming-Tsan Liu, Pei-Wen Hsiao
Seasonal influenza viruses impact public health annually due to their continual evolution. However, the current inactivated seasonal vaccines provide poor protection against antigenically drifted viruses and require periodical reformulation through hit-and-miss predictions about which strains will circulate during the next season. To reduce the impact caused by vaccine mismatch, we investigated the drift-tolerance of virus-like particles (VLP) as an improved vaccine candidate. The cross-protective humoral immunity elicited by the H3N2-VLP vaccine constructed for the 2011-2012 season was examined against viruses isolated from 2010 to 2015 in Taiwan evolving chronologically through clades 1, 4, 5, 3B and 3C, as well as viruses that were circulating globally in 2005, 2007 and 2009...
January 13, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28065477/quantitative-analysis-of-the-yield-of-avian-h7-influenza-virus-haemagglutinin-protein-produced-in-silkworm-pupae-with-the-use-of-the-codon-optimized-dna-a-possible-oral-vaccine
#3
Kuniaki Nerome, Sayaka Matsuda, Kenichi Maegawa, Shigeo Sugita, Kazumichi Kuroda, Kazunori Kawasaki, Reiko Nerome
In this study, we aimed to quantitatively compare the increased production of three H7 influenza virus-like particle (VLP) haemagglutinin (HA) with the use of a codon-optimized single HA gene in silkworm pupae. Recombinant baculovirus (Korea H7-BmNPV) could produce 0.40 million HA units per pupa, corresponding to 1832μg protein. The yield of the HA produced in larva was estimated to be approximately 0.31 million HA units per larva, and there were no significant differences between the three HA proteins. We could establish efficient recovery system of HA production in larvae and pupae with the use of three cycles sonication methods...
January 5, 2017: Vaccine
https://www.readbyqxmd.com/read/28061848/multi-antigen-avian-influenza-a-h7n9-virus-like-particles-particulate-characterizations-and-immunogenicity-evaluation-in-murine-and-avian-models
#4
Che-Ming Jack Hu, Chu-Yang Chien, Ming-Tsan Liu, Zih-Syun Fang, Sui-Yuan Chang, Rong-Huay Juang, Shih-Chung Chang, Hui-Wen Chen
BACKGROUND: Human infection with avian influenza A virus (H7N9) was first reported in China in March 2013. Since then, hundreds of cases have been confirmed showing severe symptoms with a high mortality rate. The virus was transmitted from avian species to humans and has spread to many neighboring areas, raising serious concerns over its pandemic potential. Towards containing the disease, the goal of this study is to prepare a virus-like particle (VLP) that consists of hemagglutinin (HA), neuraminidase (NA) and matrix protein 1 (M1) derived from the human isolate A/Taiwan/S02076/2013(H7N9) for potential vaccine development...
January 7, 2017: BMC Biotechnology
https://www.readbyqxmd.com/read/28057256/biomedical-and-catalytic-opportunities-of-virus-like-particles-in-nanotechnology
#5
REVIEW
B Schwarz, M Uchida, T Douglas
Within biology, molecules are arranged in hierarchical structures that coordinate and control the many processes that allow for complex organisms to exist. Proteins and other functional macromolecules are often studied outside their natural nanostructural context because it remains difficult to create controlled arrangements of proteins at this size scale. Viruses are elegantly simple nanosystems that exist at the interface of living organisms and nonliving biological machines. Studied and viewed primarily as pathogens to be combatted, viruses have emerged as models of structural efficiency at the nanoscale and have spurred the development of biomimetic nanoparticle systems...
2017: Advances in Virus Research
https://www.readbyqxmd.com/read/28056100/chimeric-l2-based-virus-like-particle-vlp-vaccines-targeting-cutaneous-human-papillomaviruses-hpv
#6
Bettina Huber, Christina Schellenbacher, Saeed Shafti-Keramat, Christoph Jindra, Neil Christensen, Reinhard Kirnbauer
Common cutaneous human papillomavirus (HPV) types induce skin warts, whereas species beta HPV are implicated, together with UV-radiation, in the development of non-melanoma skin cancer (NMSC) in immunosuppressed patients. Licensed HPV vaccines contain virus-like particles (VLP) self-assembled from L1 major capsid proteins that provide type-restricted protection against mucosal HPV infections causing cervical and other ano-genital and oro-pharyngeal carcinomas and warts (condylomas), but do not target heterologous HPV...
2017: PloS One
https://www.readbyqxmd.com/read/28040513/novel-chimeric-virus-like-particles-vaccine-displaying-mers-cov-receptor-binding-domain-induce-specific-humoral-and-cellular-immune-response-in-mice
#7
Chong Wang, Xuexing Zheng, Weiwei Gai, Gary Wong, Hualei Wang, Hongli Jin, Na Feng, Yongkun Zhao, Weijiao Zhang, Nan Li, Guoxing Zhao, Junfu Li, Jinghua Yan, Yuwei Gao, Guixue Hu, Songtao Yang, Xianzhu Xia
Middle East respiratory syndrome coronavirus (MERS-CoV) has continued spreading since its emergence in 2012 with a mortality rate of 35.6%, and is a potential pandemic threat. Prophylactics and therapies are urgently needed to address this public health problem. We report here the efficacy of a vaccine consisting of chimeric virus-like particles (VLP) expressing the receptor binding domain (RBD) of MERS-CoV. In this study, a fusion of the canine parvovirus (CPV) VP2 structural protein gene with the RBD of MERS-CoV can self-assemble into chimeric, spherical VLP (sVLP)...
December 28, 2016: Antiviral Research
https://www.readbyqxmd.com/read/28004837/the-de-and-fg-loops-of-the-hpv-major-capsid-protein-contribute-to-the-epitopes-of-vaccine-induced-cross-neutralising-antibodies
#8
Sara L Bissett, Anna Godi, Simon Beddows
The human papillomavirus (HPV) vaccines consist of major capsid protein (L1) virus-like particles (VLP) and are highly efficacious against the development of cervical cancer precursors attributable to oncogenic genotypes, HPV16 and HPV18. A degree of vaccine-induced cross-protection has also been demonstrated against genetically-related genotypes in the Alpha-7 (HPV18-like) and Alpha-9 (HPV16-like) species groups which is coincident with the detection of L1 cross-neutralising antibodies. In this study the L1 domains recognised by inter-genotype cross-neutralising antibodies were delineated...
December 22, 2016: Scientific Reports
https://www.readbyqxmd.com/read/28003597/safety-and-immunogenicity-study-of-a-9-valent-human-papillomavirus-vaccine-administered-to-9-to-15-year-old-japanese-girls
#9
Satoshi Iwata, Shinya Murata, Shi Rong Han, Akira Wakana, Miyuki Sawata, Yoshiyuki Tanaka
A 9-valent human papillomavirus (HPV 6/11/16/18/31/33/45/52/58) virus-like particle (VLP) vaccine (9vHPV) has been proven highly efficacious in preventing anogenital disease related with vaccine HPV types in a pivotal Phase III study in women aged 16 to 26 years. We report here the results of an open-label phase III study conducted to bridge the findings in women age 16 to 26 years to Japanese girls aged 9 to 15 years. All subjects (n = 100) received a 3-dose regimen of 9vHPV vaccine at day 1, month 2 and month 6...
December 22, 2016: Japanese Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28000050/merkel-cell-polyomavirus-igg-antibody-levels-are-associated-with-progression-to-aids-among-hiv-infected-individuals
#10
Rouhollah Vahabpour, Maryam Nasimi, Niloofar Naderi, Mostafa Salehi-Vaziri, Nasir Mohajel, Farzin Sadeghi, Hossein Keyvani, Seyed Hamidreza Monavari
The association of Merkel cell polyomavirus (MCPyV) with Merkel cell carcinoma (MCC) in immunocompromised individuals has been revealed in a number of surveys. The study of MCPyV specific antibody titers and viral loads in such patients has a great attraction for research groups interested in viral reactivation. In this cross-sectional study to evaluate MCPyV antibody titer, DNA prevalence and viral load in peripheral blood mononuclear cells (PBMCs), we examined 205 HIV-1 infected patients and 100 un-infected controls...
December 20, 2016: Archives of Virology
https://www.readbyqxmd.com/read/27999340/equine-immunoglobulin-and-equine-neutralizing-f-ab-%C3%A2-protect-mice-from-west-nile-virus-infection
#11
Jiannan Cui, Yongkun Zhao, Hualei Wang, Boning Qiu, Zengguo Cao, Qian Li, Yanbo Zhang, Feihu Yan, Hongli Jin, Tiecheng Wang, Weiyang Sun, Na Feng, Yuwei Gao, Jing Sun, Yanqun Wang, Stanley Perlman, Jincun Zhao, Songtao Yang, Xianzhu Xia
West Nile virus (WNV) is prevalent in Africa, Europe, the Middle East, West Asia, and North America, and causes epidemic encephalitis. To date, no effective therapy for WNV infection has been developed; therefore, there is urgent need to find an efficient method to prevent WNV disease. In this study, we prepared and evaluated the protective efficacy of immune serum IgG and pepsin-digested F(ab')₂ fragments from horses immunized with the WNV virus-like particles (VLP) expressing the WNV M and E proteins. Immune equine F(ab')₂ fragments and immune horse sera efficiently neutralized WNV infection in tissue culture...
December 18, 2016: Viruses
https://www.readbyqxmd.com/read/27998269/increased-t-cell-breadth-and-antibody-response-elicited-in-prime-boost-regimen-by-viral-vector-encoded-homologous-siv-gag-env-in-outbred-cd1-mice
#12
Anne-Marie Carola Andersson, Peter Johannes Holst
BACKGROUND: A major obstacle for the development of HIV vaccines is the virus' worldwide sequence diversity. Nevertheless, the presence of T cell epitopes within conserved regions of the virus' structural Gag protein and conserved structures in the envelope (env) sequence raises the possibility that cross-reactive responses may be induced by vaccination. In this study, the aim was to investigate the importance of antigenic match on immunodominance and breadth of obtainable T cell responses...
December 20, 2016: Journal of Translational Medicine
https://www.readbyqxmd.com/read/27997339/toll-like-receptor-3-adjuvant-in-combination-with-virus-like-particles-elicit-a-humoral-response-against-hiv
#13
Ethan Poteet, Phoebe Lewis, Changyi Chen, Sam On Ho, Thai Do, SuMing Chiang, Celia Labranche, David Montefiori, Gary Fujii, Qizhi Yao
Human Immunodeficiency Virus (HIV) Virus-Like Particles (VLPs) composed of HIVIIIB Gag and HIVBaL gp120/gp41 envelope are a pseudovirion vaccine capable of presenting antigens in their native conformations. To enhance the immunogenicity of the HIV Env antigen, VLPs were coupled to VesiVax Conjugatable Adjuvant Lipid Vesicles (CALV) containing one of four toll-like-receptor (TLR) ligands, each activating a receptor with distinct cellular localization and downstream pathways. C57BL/6 mice were vaccinated by intranasal prime followed by two sub-cheek boosts and their sera immunoglobulin and neutralizing potency were measured over a duration of 3months after vaccination...
November 21, 2016: Vaccine
https://www.readbyqxmd.com/read/27974288/virus-like-particle-vaccine-by-intranasal-vaccination-elicits-protective-immunity-against-respiratory-syncytial-viral-infection-in-mice
#14
Mengying Cai, Cheng Wang, Yufeng Li, Hongjing Gu, Sujing Sun, Yueqiang Duan, Chengcai Lai, Keyu Wang, Xiaolan Yang, Li Xing, Peirui Zhang, Zhaohai Wang, Shaogeng Zhang, Xiaodong Guo, Shubing Liu, Yigang Tong, Xiliang Wang, Penghui Yang
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory infection in infants and children, but there is still no licensed vaccine available. In this report, we developed virus-like particle (VLP) vaccines based on the Bac-to-Bac baculovirus expression system, consisting of an influenza virus matrix (M1) protein and the RSV fusion protein (F) or glycoprotein (G). These RSV VLPs were identified by western blot analysis and electron microscopy. Female BALB/c mice immunized intranasally (i.n.) with RSV-F VLPs, RSV-G VLPs, or both showed viral-specific antibody responses against RSV...
January 2017: Acta Biochimica et Biophysica Sinica
https://www.readbyqxmd.com/read/27938681/characterization-of-the-role-in-adherence-of-mycoplasma-hyorhinis-variable-lipoproteins-containing-different-repeat-unit-copy-numbers
#15
Qiyan Xiong, Bixiong Zhang, Jia Wang, Bo Ni, Yan Ji, Yanna Wei, Shaobo Xiao, Zhixin Feng, Maojun Liu, Guoqing Shao
Mycoplasma hyorhinis (M. hyorhinis) is an important pathogen of pigs. In previous studies, the variable lipoprotein (Vlp) family has been shown to play a role in mediating M. hyorhinis cytoadhesion. Herein, we performed several experiments to study the function of each Vlp family member in detail, especially examining the cytoadhesion functional domain and how the repeat unit copy number impacts on function. Recombinant proteins rVlpII, composed of region II from all seven Vlp members; rVlpIII, composed of repeat peptides from region III of all of Vlp members; as well as a series of recombinant rVlp proteins for each member containing different repeat unit copy numbers were constructed...
December 25, 2016: Veterinary Microbiology
https://www.readbyqxmd.com/read/27928008/increasing-type-1-poliovirus-capsid-stability-by-thermal-selection
#16
Oluwapelumi O Adeyemi, Clare Nicol, Nicola J Stonehouse, David J Rowlands
: Poliomyelitis is a highly infectious disease caused by poliovirus (PV). It can result in paralysis and may be fatal. Integrated global immunisation programmes using live-attenuated oral (OPV) and/or inactivated PV vaccines (IPV) have systematically reduced its spread and paved the way for eradication. Immunisation will continue post-eradication to ensure against reintroduction of the disease, but there are biosafety concerns for both OPV and IPV. These could be addressed by the production and use of virus-free virus-like particle (VLP) vaccines which mimic the 'empty' capsids (ECs) normally produced in viral infection...
December 7, 2016: Journal of Virology
https://www.readbyqxmd.com/read/27928002/adjuvanting-an-siv-vaccine-with-tlr-ligands-encapsulated-in-nanoparticles-induces-persistent-antibody-responses-and-enhanced-protection-in-trim5%C3%AE-restrictive-macaques
#17
Sudhir Pai Kasturi, Pamela A Kozlowski, Helder I Nakaya, Matheus C Burger, Pedro Russo, Mathew Pham, Yevgeniy Kovalenkov, Eduardo L V Silveira, Colin Havenar-Daughton, Samantha L Burton, Katie M Kilgore, Mathew J Johnson, Rafiq Nabi, Traci Legere, Zarpheen Jinnah Sher, Xuemin Chen, Rama R Amara, Eric Hunter, Steven E Bosinger, Paul Spearman, Shane Crotty, Francois Villinger, Cynthia A Derdeyn, Jens Wrammert, Bali Pulendran
: Our previous work has shown that antigens adjuvanted with specific ligands for toll-like receptor 4 (TLR4) and TLR7/8 encapsulated in poly (lactic-co-glycolic acid) (PLGA) based nanoparticles (NP), induced robust and durable immune responses in mice and macaques. We investigated the efficacy of these NP adjuvants in inducing protective immunity against simian immunodeficiency virus (SIV). Rhesus macaques (RMs) were immunized with NP containing TLR4 and TLR7/8 agonists mixed with soluble recombinant SIVmac239 derived envelope (Env) gp140 and Gag p55 (Protein), or with virus like particles (VLP) containing SIVmac239 Env and Gag...
December 7, 2016: Journal of Virology
https://www.readbyqxmd.com/read/27926826/potential-of-a-bpv1-l1-vlp-vaccine-to-prevent-bpv1-or-bpv2-induced-pseudo-sarcoid-formation-and-safety-and-immunogenicity-of-ecpv2-l1-vlps-in-the-horse
#18
Edmund K Hainisch, Hans Abel-Reichwald, Saeed Shafti-Keramat, Barbara Pratscher, Annunziata Corteggio, Giuseppe Borzacchiello, Maria Wetzig, Christoph Jindra, Alexander Tichy, Reinhard Kirnbauer, Sabine Brandt
We have previously shown that immunization of horses with BPV1 L1 virus-like particles (VLP) is safe and highly immunogenic, and that bovine papillomavirus types 1 and 2 (BPV1, BPV2) are closely related serotypes. Here we evaluated the protective potential of a BPV1 L1 VLP vaccine against experimental BPV1 and BPV2 challenge, and studied the safety and immunogenicity of a bivalent EcPV2/BPV1 L1 VLP vaccine. Fourteen healthy horses were immunized with BPV1 L1 VLPs (100 µg/injection) plus adjuvant on days 0 and 28, whilst seven remained unvaccinated...
December 7, 2016: Journal of General Virology
https://www.readbyqxmd.com/read/27926486/novel-epstein-barr-virus-like-particles-incorporating-gh-gl-ebna1-or-gb-lmp2-induce-high-neutralizing-antibody-titers-and-ebv-specific-t-cell-responses-in-immunized-mice
#19
Elizabeth M Perez, Joslyn Foley, Timelia Tison, Rute Silva, Javier Gordon Ogembo
Previous Epstein-Barr virus (EBV) prophylactic vaccines based on the major surface glycoprotein gp350/220 as an immunogen have failed to block viral infection in humans, suggesting a need to target other viral envelope glycoproteins. In this study, we reasoned that incorporating gH/gL or gB, critical glycoproteins for viral fusion and entry, on the surface of a virus-like particle (VLP) would be more immunogenic than gp350/220 for generating effective neutralizing antibodies to prevent viral infection of both epithelial and B cell lines...
December 1, 2016: Oncotarget
https://www.readbyqxmd.com/read/27920180/whole-inactivated-and-virus-like-particle-vaccine-strategies-for-chikungunya-virus
#20
Adam D DeZure, Nina M Berkowitz, Barney S Graham, Julie E Ledgerwood
Chikungunya virus (CHIKV) is a global public health threat, having been identified in >60 countries in Asia, Africa, Europe, and the Americas. There is no cure for or licensed vaccine against CHIKV infection. Initial attempts at CHIKV vaccine development began in the early 1960s. Whole-inactivated and virus-like particle (VLP) vaccines are 2 of the current approaches being evaluated. Success of these approaches is dependent on a safe, well-tolerated vaccine that is immunogenic and deployable in regard to manufacturing, stability, and delivery characteristics...
December 15, 2016: Journal of Infectious Diseases
keyword
keyword
7257
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"